Analysis of Circulating Tumor Markers in Blood - ALCINA 5
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
About this trial
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Eligibility criteria
Qualifiers
Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
18 years old or higher ?
Patient who has provided informed, written, and explicit consent,
Patient affiliated with a French Social Protection System.
Disqualifiers
Pregnant woman and/or breast-feeding,
Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
Private persons of freedom or under guardianship,
Patient with a history of other invasive cancers within the 5 years preceding inclusion.
Trial design
Treatments tested in this trial
- Blood sampling C1
Treatment groups
620 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov